Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02594163 · ClinicalTrials.gov registry record · Phase 2
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
A Phase 2 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT02594163 is a Phase 2 study that was terminated before completion, run by Seagen. The registered enrollment target is 25 participants.
The verdict
NCT02594163, a Phase 2 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin in combination with rituximab and bendamustine for the treatment of patients with relapsed or refractory CD30-positive diffuse large B-cell lymphoma (DLBCL) after failure of second-line salvage therapy or as second-line treatment in patients ineligible for autologous stem cell transplant (ASCT).
Interventions
- DRUG Rituximab
- DRUG Brentuximab Vedotin
- DRUG Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02594163
The ClinicalTrials.gov registry entry for NCT02594163 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT02594163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02594163 about?
NCT02594163 is a clinical study titled "Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma". This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin in combination with rituximab and bendamustine for the treatment of patients with relapsed or refractory CD30-positive diffuse large B-cell lymphoma (DLBCL) after...
What is the current status of trial NCT02594163?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-10. Estimated completion is 2017-09.
What interventions are being tested in trial NCT02594163?
The interventions under investigation include: Rituximab (DRUG), Brentuximab Vedotin (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT02594163?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.